156 related articles for article (PubMed ID: 25354554)
1. The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.
Söderlund Leifler K; Asklid A; Fornander T; Stenmark Askmalm M
J Cancer Res Clin Oncol; 2015 May; 141(5):797-804. PubMed ID: 25354554
[TBL] [Abstract][Full Text] [Related]
2. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
Antoniou AC; Sinilnikova OM; Simard J; Léoné M; Dumont M; Neuhausen SL; Struewing JP; Stoppa-Lyonnet D; Barjhoux L; Hughes DJ; Coupier I; Belotti M; Lasset C; Bonadona V; Bignon YJ; ; Rebbeck TR; Wagner T; Lynch HT; Domchek SM; Nathanson KL; Garber JE; Weitzel J; Narod SA; Tomlinson G; Olopade OI; Godwin A; Isaacs C; Jakubowska A; Lubinski J; Gronwald J; Górski B; Byrski T; Huzarski T; Peock S; Cook M; Baynes C; Murray A; Rogers M; Daly PA; Dorkins H; ; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Niederacher D; Deissler H; ; Spurdle AB; Chen X; Waddell N; Cloonan N; ; Kirchhoff T; Offit K; Friedman E; Kaufmann B; Laitman Y; Galore G; Rennert G; Lejbkowicz F; Raskin L; Andrulis IL; Ilyushik E; Ozcelik H; Devilee P; Vreeswijk MP; Greene MH; Prindiville SA; Osorio A; Benitez J; Zikan M; Szabo CI; Kilpivaara O; Nevanlinna H; Hamann U; Durocher F; Arason A; Couch FJ; Easton DF; Chenevix-Trench G;
Am J Hum Genet; 2007 Dec; 81(6):1186-200. PubMed ID: 17999359
[TBL] [Abstract][Full Text] [Related]
3. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
[TBL] [Abstract][Full Text] [Related]
4. [Association of polymorphisms of N372H in BRCA2 gene and 135G/C in RAD51 gene and breast cancers].
Hu R; Wei Y; Jiang WJ; Yao WX; Long QM; Zhang JH; Liang Y; Tang XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Nov; 39(6):973-5. PubMed ID: 19253839
[TBL] [Abstract][Full Text] [Related]
5. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
Söderlund K; Skoog L; Fornander T; Askmalm MS
Radiother Oncol; 2007 Sep; 84(3):242-51. PubMed ID: 17707537
[TBL] [Abstract][Full Text] [Related]
6. RAD51 genotype and triple-negative breast cancer (TNBC) risk in Polish women.
Smolarz B; Zadrożny M; Duda-Szymańska J; Makowska M; Samulak D; Michalska MM; Mojs E; Bryś M; Forma E; Romanowicz-Makowska H
Pol J Pathol; 2013 Apr; 64(1):39-43. PubMed ID: 23625599
[TBL] [Abstract][Full Text] [Related]
7. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
8. Positive effect of single nucleotide RAD51 135G>C polymorphism and low Ku70 protein expression on female rectal cancer patients survival after preoperative radiotherapy.
Gasinska A; Biesaga B; Widla AJ; Darasz Z
Turk J Gastroenterol; 2019 Jan; 30(1):3-14. PubMed ID: 30289394
[TBL] [Abstract][Full Text] [Related]
9. Association between polymorphisms of the DNA repair gene RAD51 and ovarian cancer.
Smolarz B; Makowska M; Samulak D; Michalska MM; Mojs E; Romanowicz H; Wilczak M
Pol J Pathol; 2013 Dec; 64(4):290-5. PubMed ID: 24375044
[TBL] [Abstract][Full Text] [Related]
10. Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
Kim K; Chie EK; Han W; Noh DY; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
Tumori; 2011; 97(3):280-5. PubMed ID: 21789003
[TBL] [Abstract][Full Text] [Related]
11. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Specht K; Harbeck N; Smida J; Annecke K; Reich U; Naehrig J; Langer R; Mages J; Busch R; Kruse E; Klein-Hitpass L; Schmitt M; Kiechle M; Hoefler H
Breast Cancer Res Treat; 2009 Nov; 118(1):45-56. PubMed ID: 18925433
[TBL] [Abstract][Full Text] [Related]
13. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Przybylowska-Sygut K; Stanczyk M; Kusinska R; Kordek R; Majsterek I
Clin Breast Cancer; 2013 Feb; 13(1):61-8. PubMed ID: 23103366
[TBL] [Abstract][Full Text] [Related]
14. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
15. RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies.
Gao LB; Pan XM; Li LJ; Liang WB; Zhu Y; Zhang LS; Wei YG; Tang M; Zhang L
Breast Cancer Res Treat; 2011 Feb; 125(3):827-35. PubMed ID: 20640595
[TBL] [Abstract][Full Text] [Related]
16. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.
Kadouri L; Kote-Jarai Z; Hubert A; Durocher F; Abeliovich D; Glaser B; Hamburger T; Eeles RA; Peretz T
Br J Cancer; 2004 May; 90(10):2002-5. PubMed ID: 15138485
[TBL] [Abstract][Full Text] [Related]
17. p53 expression and the result of adjuvant therapy of breast cancer.
Stål O; Stenmark Askmalm M; Wingren S; Rutqvist LE; Skoog L; Ferraud L; Sullivan S; Carstensen J; Nordenskjöld B
Acta Oncol; 1995; 34(6):767-70. PubMed ID: 7576743
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
19. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.
Arcangeli G; Pinnarò P; Rambone R; Giannarelli D; Benassi M
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):161-7. PubMed ID: 16226397
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer.
Lamb D; Atkinson C; Joseph D; O'Brien P; Ackland S; Bonaventura A; Dady P; Hamilton C; Spry N; Stewart J; Denham J
Australas Radiol; 1999 May; 43(2):220-6. PubMed ID: 10901906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
